(NASDAQ: BNTC) Benitec Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.
Benitec Biopharma's earnings in 2026 is -$45,546,000.On average, 10 Wall Street analysts forecast BNTC's earnings for 2027 to be -$44,388,269, with the lowest BNTC earnings forecast at -$50,252,055, and the highest BNTC earnings forecast at -$38,824,474. On average, 7 Wall Street analysts forecast BNTC's earnings for 2028 to be -$47,109,121, with the lowest BNTC earnings forecast at -$59,482,024, and the highest BNTC earnings forecast at -$21,609,849.
In 2029, BNTC is forecast to generate -$41,719,740 in earnings, with the lowest earnings forecast at -$76,232,709 and the highest earnings forecast at $10,988,059.